Recent Research Analysts’ Ratings Changes for Gilead Sciences (GILD)

A number of research firms have changed their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

• 10/21/2024 – Gilead Sciences was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 10/21/2024 – Gilead Sciences was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $96.00 price target on the stock, up previously from $74.00.
• 10/17/2024 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $85.00 to $94.00. They now have an “outperform” rating on the stock.
• 10/17/2024 – Gilead Sciences is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $105.00 price target on the stock.
• 10/9/2024 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $95.00 to $100.00. They now have an “overweight” rating on the stock.
• 10/7/2024 – Gilead Sciences was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $100.00 price target on the stock, up previously from $78.00.
• 10/7/2024 – Gilead Sciences had its price target raised by analysts at Barclays PLC from $76.00 to $84.00. They now have an “equal weight” rating on the stock.
• 10/4/2024 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $74.00 to $75.00. They now have a “sector perform” rating on the stock.
• 9/16/2024 – Gilead Sciences had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 9/11/2024 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $95.00 price target on the stock.
• 9/9/2024 – Gilead Sciences had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 9/4/2024 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $72.00 to $74.00. They now have a “sector perform” rating on the stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $88.39 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock has a market capitalization of $110.12 billion, a P/E ratio of 245.53, a P/E/G ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.07. The company’s fifty day moving average price is $81.87 and its 200 day moving average price is $73.17.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock valued at $3,033,340 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. CarsonAllaria Wealth Management Ltd. lifted its stake in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 238 shares during the last quarter. nVerses Capital LLC acquired a new stake in Gilead Sciences in the third quarter valued at $25,000. Palisade Asset Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Cedar Wealth Management LLC boosted its position in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.